For two decades, the global outsourcing conversation had two default answers: WuXi for speed and scale, Lonza for biologics and regulatory pedigree.
That default is breaking down. The India CRDMO sector is no longer a budget alternative considered only when the big names are unavailable. It is becoming a genuine third option, faster than most forecasts predicted.
The Scale Gap Is Real, But It Is Closing
Numbers first, for honest expectations.
- WuXi AppTec generated roughly $6.3 billion in CY2025 revenue, with backlog reaching RMB 58.0 billion, up nearly 29% year over year
- Indian CRDMOs collectively generated an estimated $3 to $3.5 billion in FY26 sales, per Jefferies
- Lonza invested CHF 1.3 billion in 2025 capex, including a $1.2 billion Vacaville acquisition adding 700,000 liters of bioreactor capacity
India is not close to WuXi or Lonza on raw scale. Anyone claiming otherwise is not being honest.
What has changed is the trajectory. Jefferies estimates the China plus one CRDMO shift could add roughly $700 million in annual revenue to Indian CRDMOs, with $2.4 billion in incremental gains over four years. That estimate accelerated after WuXi AppTec was added to the US Department of Defense’s Section 1260H list, triggering BIOSECURE Act restrictions on federal contracting.
What Changed the Calculus
WuXi’s addition to the 1260H list is not a minor regulatory footnote. It means any US sponsor with federal funding exposure, including NIH or BARDA grants, now has a direct compliance reason to evaluate alternatives. Implementation could take 12 to 24 months, but sponsors are not waiting for enforcement deadlines to start derisking.
This is where the India CDMO capacity conversation gets specific. The opportunity is concentrated where Indian CRDMOs already do well: small molecule chemistry and peptide manufacturing, not large-scale biologics or cell and gene therapy where Lonza and WuXi still dominate.
Comparing the Three on the Factors That Actually Matter
Scale alone is the wrong benchmark for most sponsors. Here is how the comparison looks across the factors that actually drive a decision.
Regulatory track record Lonza reports more than 80 successful site inspections by 14 global health authorities over five years. WuXi AppTec completed 741 quality audits and inspections in 2025 alone with no critical findings. Leading Indian CRDMOs have built comparable USFDA and EMA inspection histories, though public audit volume is smaller simply because program counts are smaller.
Pricing This remains India’s clearest structural advantage. Indian CDMO pricing typically runs 18 to 20% below Chinese competitors, driven by labor cost differences that persist even as quality has converged.
Therapeutic and modality specialization WuXi dominates peptides and oligonucleotides, with TIDES revenue up 121% year over year through nine months of 2025. Lonza leads in mammalian biologics and ADCs. India’s strength stays concentrated in small molecule APIs, high-potency APIs, and complex chemistry including flow and continuous processes, with peptide capability still building.
Capacity flexibility WuXi and Lonza operate at a scale suited to large pharma programs and high-volume commercial manufacturing. Indian CRDMOs fit biotech-stage programs better, where close scientific collaboration matters more than sheer reactor volume.
Where the Quality-First Positioning Comes In
The old India pitch was cost. The new pitch has to be quality plus cost, because sponsors leaving China are not looking to trade one risk for another.
What separates a credible India partner from a commodity vendor:
- A genuine USFDA and EMA inspection history, not just GMP certification on paper
- In-house integration across discovery, process chemistry, and manufacturing, reducing handoff risk from stitching together multiple vendors
- Specific chemistry depth in complex, high-energy, or high-pressure synthesis, not just standard routes
- Transparent IP and data security practices suited to sponsors already wary after a forced vendor transition
How LAXAI Fits This Moment
LAXAI is built as a fully integrated small-molecule CRDMO, not a chemistry-only vendor scaling up reactively to capture China-plus-one demand.
The team covers discovery through GMP manufacturing under one roof, with over 150 completed CMC projects and specific expertise in high-energy and high-pressure chemistries that many CDMOs, Indian or otherwise, decline to handle.
LAXAI’s GMP site operates under established quality systems supporting US and EU-regulated programs. For sponsors shifting away from China-based partners, the priority is not the cheapest replacement. It is a partner with the scientific depth to take on a displaced program without losing momentum.
Talk to LAXAI’s team about your program at bd@laxai.com
FAQs
How big is India’s CRDMO sector compared to WuXi AppTec?
Indian CRDMOs collectively generated an estimated $3 to $3.5 billion in FY26 sales, compared to WuXi’s roughly $6.3 billion in CY2025. The gap is significant, but India is gaining share in small molecule and peptide chemistry.
Why is WuXi AppTec’s 1260H designation significant?
Its addition to the DoD’s Section 1260H list triggers BIOSECURE Act restrictions on federal contracting, giving US sponsors with federal funding exposure a direct compliance reason to evaluate alternative CRDMO partners.
Is India a viable alternative to Lonza for biologics?
Not yet at scale. Lonza’s strength is large-molecule biologics, ADCs, and cell and gene therapy capacity. India’s advantage stays concentrated in small molecule APIs and complex chemistry, with peptide and biologics capability still developing.
What should sponsors prioritize when evaluating an Indian CRDMO?
Regulatory inspection history, integration across discovery through manufacturing, and chemistry depth matter more than price alone, especially when transitioning a program under time pressure.
